{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["active substance", "bio-similar drugs", "biological medicinal products", "fusion proteins", "monoclonal antibodies"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": [], "GeneralNote": [], "PMID": "33316993", "DateRevised": {"Year": "2020", "Month": "12", "Day": "29"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "12", "Day": "09"}], "Language": ["eng"], "ELocationID": ["2343", "10.3390/ani10122343"], "Journal": {"ISSN": "2076-2615", "JournalIssue": {"Volume": "10", "Issue": "12", "PubDate": {"Year": "2020", "Month": "Dec", "Day": "09"}}, "Title": "Animals : an open access journal from MDPI", "ISOAbbreviation": "Animals (Basel)"}, "ArticleTitle": "Selected Biological Medicinal Products and Their Veterinary Use.", "Abstract": {"AbstractText": ["Definitions of biological medicinal products (BMPs) vary depending on the source. BMPs are manufactured using complex biological/biotechnological processes involving living cell lines, tissues and organisms such as microorganisms, plants, humans and even animals. Advances in modern biotechnological methods and genetic engineering have made it possible to search for new drugs with a targeted effect and simultaneous reduction of adverse effects, which has resulted in BMPs dynamically increasing their share in the pharmaceutical market. Currently, these drugs are widely used in the treatment of many human diseases, but an increasing number of drugs of this group are also being used in the treatment of animals, mainly in dermatology, rheumatology and oncology. This article presents the current state of knowledge in the field of biological medicinal products used in animal therapy."]}, "AuthorList": [{"Identifier": ["0000-0002-5759-3156"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Warmia and Mazury in Olsztyn, Oczapowskiego 13, 10-718 Olsztyn, Poland."}], "LastName": "Zygmuntowicz", "ForeName": "Aleksandra", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Sub-Department of Pharmacology, Toxicology and Environmental Protection, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, 12 Akademicka St., 20-950 Lublin, Poland."}], "LastName": "Burma\u0144czuk", "ForeName": "Artur", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Warmia and Mazury in Olsztyn, Oczapowskiego 13, 10-718 Olsztyn, Poland."}], "LastName": "Markiewicz", "ForeName": "W\u0142odzimierz", "Initials": "W"}], "GrantList": [{"GrantID": "15.610.008-110", "Agency": "University of Warmia and Mazury in Olsztyn", "Country": ""}, {"GrantID": "010/RID/2018/19", "Agency": "Ministerstwo Nauki i Szkolnictwa Wy\u017cszego", "Country": ""}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Animals (Basel)", "NlmUniqueID": "101635614", "ISSNLinking": "2076-2615"}, "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Sobell J.M. Overview of biologic agents in medicine and dermatology. Semin. Cutan. Med. Surg. 2005;24:2\u20139. doi: 10.1016/j.sder.2005.01.007.", "ArticleIdList": ["10.1016/j.sder.2005.01.007", "15900793"]}, {"Citation": "Hansel T.T., Kropshofer H., Singer T. The safety and side effects of monoclonal antibodies. Nat. Rev. Drug. Discov. 2010;9:325\u2013338. doi: 10.1038/nrd3003.", "ArticleIdList": ["10.1038/nrd3003", "20305665"]}, {"Citation": "United States Department of Agriculture (USDA)  Veterinary Biological Products.  [(accessed on 8 October 2020)];2020  Available online:  https://www.aphis.usda.gov/animal_health/vet_biologics/publications/currentprodcodebook.pdf."}, {"Citation": "Public Health Service Act  Section 351 (i) (1)  [(accessed on 14 October 2020)]; Available online:  https://legcounsel.house.gov/Comps/PHSA-merged.pdf."}, {"Citation": "United States Department of Agriculture (USDA)  Veterinary Biologics. Use and Regulation.  [(accessed on 14 October 2020)]; Available online:  https://www.aphis.usda.gov/publications/animal_health/content/printable_version/vet_biologics.pdf."}, {"Citation": "European Medicines Agency (EMA)  EMA/837805/2011. Question and Answers on Biosimilar Medicines (Similar Biological Medicinal Products)  [(accessed on 14 October 2020)]; Available online:  https://www.medicinesforeurope.com/wpontent/uploads/2016/03/WC500020062.pdf."}, {"Citation": "Rosenfeld L. Insulin: Discovery and controversy. Clin. Chem. 2002;48:2270\u20132288. doi: 10.1093/clinchem/48.12.2270.", "ArticleIdList": ["10.1093/clinchem/48.12.2270", "12446492"]}, {"Citation": "Borkowski L. Biological biosimilars are available in pharmacies. Apt. Pol. 2017;134:21\u201328."}, {"Citation": "Statistical Data  Number of Pigs Worldwide from 2012 to 2020 (in Million Head)  [(accessed on 14 October 2020)]; Available online:  https://www.statista.com/statistics/263964/number-of-pigs-in-selected-countries/"}, {"Citation": "Baeshen N.A., Baeshen M.N., Sheikh A., Bora R.S., Ahmed M.M.M., Ramadan H.A.I., Saini K.S., Redwan E.M. Cell factories for insulin production. Microb. Cell. Fact. 2014;13:141. doi: 10.1186/s12934-014-0141-0.", "ArticleIdList": ["10.1186/s12934-014-0141-0", "PMC4203937", "25270715"]}, {"Citation": "Ciarkowska A., Jakubowska A. Pichia pastoris as an expression system for recombinant protein production. Post. Bioch. 2013;59:315\u2013321.", "ArticleIdList": ["24364214"]}, {"Citation": "European Medicines Agency (EMA)  Human Medicines Highlights 2019.  [(accessed on 14 October 2020)]; Available online:  https://www.ema.europa.eu/en/documents/report/human-medicines-highlights-2019_en.pdf."}, {"Citation": "Food and Drug Administration (FDA)  New Drug Therapy Approvals 2019.  [(accessed on 14 October 2020)]; Available online:  https://www.fda.gov/media/134493/download."}, {"Citation": "Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 Laying Down Community Procedures for the Authorisation and Supervision of Medicinal Products for Human and Veterinary Use and Establishing a European Medicines Agency (OJ L 136, 30.4.2004, p. 1\u201333)  [(accessed on 14 October 2020)]; Available online:  https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2004_726/reg_2004_726_pl.pdf."}, {"Citation": "European Medicines Agency (EMA)  EMA/716925/2016. The European Regulatory System for Medicines. A Consistent Approach to Medicines Regulation Across the European Union.  [(accessed on 14 October 2020)]; Available online:  https://www.ema.europa.eu/en/documents/leaflet/european-regulatory-system-medicines-european-medicines-agency-consistent-approach-medicines_en.pdf."}, {"Citation": "Finnish Medicines Agency (FIMEA)  Biological Medicinal Products.  [(accessed on 14 October 2020)]; Available online:  https://www.fimea.fi/web/en/pharmaceutical_safety_and_information/biological-medicinal-products."}, {"Citation": "U.S. Food and Drug Administration (FDA)  Considerations in Demonstrating Interchangeability with a Reference Product.  [(accessed on 14 October 2020)]; Available online:  https://www.fda.gov/media/124907/download."}, {"Citation": "United States Department of Agriculture (USDA)  Veterinary Biologics.  [(accessed on 14 October 2020)]; Available online:  https://www.aphis.usda.gov/aphis/ourfocus/animalhealth/veterinary-biologics."}, {"Citation": "U.S. Food and Drug Administration (FDA)  Scientific Considerations in Demonstrating Biosimilarity to a Reference Product.  [(accessed on 14 October 2020)]; Available online:  https://www.fda.gov/media/82647/download."}, {"Citation": "U.S. Food and Drug Administration (FDA)  Information for Healthcare Professionals (Drugs)  [(accessed on 14 October 2020)]; Available online:  https://www.fda.gov/drugs/resources-you-drugs/information-healthcare-professionals-drugs."}, {"Citation": "Liberek T., Wo\u0142yniec W., Renke M., Weber E., Rutkowski B. Biopharmaceutics in nephrology. Forum Nefrologiczne. 2013;6:139\u2013149."}, {"Citation": "Singri P., West D., Gordon K. Biologic therapy for psoriasis. The new therapeutic frontier. Arch. Dermatol. 2002;138:657\u2013663. doi: 10.1001/archderm.138.5.657.", "ArticleIdList": ["10.1001/archderm.138.5.657", "12020229"]}, {"Citation": "Lohner M.E., Krueger J.G., Gottlieb A. Clinical trials of a fully human anti-IL-8 antibody for the treatment of psoriasis. Br. J. Dermatol. 1999;141:989."}, {"Citation": "Jones T.D., Carter P.J., Pl\u00fcckthun A., V\u00e1squez M., Holgate R.G.E., H\u00f6tzel I., Popplewell A.G., Parren P.W.H.I., Enzelberger M., Rademaker H.J., et al. The INNs and outs of antibody nonproprietary names. MAbs. 2016;8:1\u20139. doi: 10.1080/19420862.2015.1114320.", "ArticleIdList": ["10.1080/19420862.2015.1114320", "PMC4966553", "26716992"]}, {"Citation": "Parren P.W.H.I., Carter P.J., Pl\u00fcckthun A. Changes to International Non-Proprietary Names for antibody therapeutics 2017 and beyond of mice, men and more. MAbs. 2017;9:898\u2013906. doi: 10.1080/19420862.2017.1341029.", "ArticleIdList": ["10.1080/19420862.2017.1341029", "PMC5590622", "28621572"]}, {"Citation": "World Health Organization (WHO)  Selection Process of INNs.  [(accessed on 14 October 2020)]; Available online:  https://www.who.int/medicines/services/inn/selection/en/"}, {"Citation": "Mayrhofer P., Kunert R. Nomenclature of humanized mAbs: Early concepts, current challenges and future perspectives. Hum. Antib. 2019;27:37\u201351. doi: 10.3233/HAB-180347.", "ArticleIdList": ["10.3233/HAB-180347", "PMC6294595", "30103312"]}, {"Citation": "Gao F., Chiu S.M., Motan D.A.L., Zhang Z., Chen L., Ji H.L., Tse H.F., Fu Q.L., Lian Q. Mesenchymal stem cells and immunomodulation: Current status and future prospects. Cell Death Dis. 2016;7:e2062. doi: 10.1038/cddis.2015.327.", "ArticleIdList": ["10.1038/cddis.2015.327", "PMC4816164", "26794657"]}, {"Citation": "Gattegno-Ho D., Argyle S.A., Argyle D.J. Stem cells and veterinary medicine: Tools to understand diseases and enable tissue regeneration and drug discovery. Vet. J. 2012;191:19\u201327. doi: 10.1016/j.tvjl.2011.08.007.", "ArticleIdList": ["10.1016/j.tvjl.2011.08.007", "21958722"]}, {"Citation": "Brunt K.R., Weisel R.D., Li R.K. Stem cells and regenerative medicine\u2014Future perspectives. Can. J. Physiol. Pharmacol. 2012;90:327\u2013335. doi: 10.1139/y2012-007.", "ArticleIdList": ["10.1139/y2012-007", "22401558"]}, {"Citation": "Dias I.E., Pinto P.O., Barros L.C., Viegas C.A., Dias I.R., Carvalho P.P. Mesenchymal stem cells therapy in companion animals: Useful for immune-mediated diseases? BMC Vet. Res. 2019;15:358. doi: 10.1186/s12917-019-2087-2.", "ArticleIdList": ["10.1186/s12917-019-2087-2", "PMC6805418", "31640767"]}, {"Citation": "Newman R.E., Yoo D., LeRoux M.A., Danilkovitch-Miagkova A. Treatment of Inflammatory Diseases with Mesenchymal Stem Cells. Inflamm. Allergy Drug Targets. 2009;8:110\u2013123. doi: 10.2174/187152809788462635.", "ArticleIdList": ["10.2174/187152809788462635", "19530993"]}, {"Citation": "Johnston S.L. Biologic therapies: What and when? J. Clin. Path. 2007;60:8\u201317. doi: 10.1136/jcp.2005.032300.", "ArticleIdList": ["10.1136/jcp.2005.032300", "PMC1860592", "17213345"]}, {"Citation": "Paluchowska E., Owczarek W., Jahnz-R\u00f3\u017cyk K. Psoriasis biological treatment in Poland. Zdrowie Publiczne Zarz\u0105dz. 2013;11:69\u201378."}, {"Citation": "Crooke S.T. Molecular mechanisms of antisense oligonucleotides. Nucleic Acid Ther. 2017;27:70\u201377. doi: 10.1089/nat.2016.0656.", "ArticleIdList": ["10.1089/nat.2016.0656", "PMC5372764", "28080221"]}, {"Citation": "Bennett C.F., Krainer A.R., Cleveland D.W. Antisense Oligonucleotide Therapies for Neurodegenerative Diseases. Annu. Rev. Neurosci. 2019;42:385\u2013406. doi: 10.1146/annurev-neuro-070918-050501.", "ArticleIdList": ["10.1146/annurev-neuro-070918-050501", "PMC7427431", "31283897"]}, {"Citation": "Lenartowicz E., Nogales A., Kierzek E., Kierzek R., Mart\u00ednez-Sobrido L., Turner D.H. Antisense Oligonucleotides Targeting Influenza A Segment 8 Genomic RNA Inhibit Viral Replication. Nucleic Acid Ther. 2016;26:277\u2013285. doi: 10.1089/nat.2016.0619.", "ArticleIdList": ["10.1089/nat.2016.0619", "PMC5067832", "27463680"]}, {"Citation": "Moreno P.M.D., P\u00eago A.P. Therapeutic antisense oligonucleotides against cancer: Hurdling to the clinic. Front. Chem. 2014;2:87. doi: 10.3389/fchem.2014.00087.", "ArticleIdList": ["10.3389/fchem.2014.00087", "PMC4196572", "25353019"]}, {"Citation": "Agarwala A., Jones P., Nambi V. The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: Risks, benefits, and management recommendations. Curr. Atheroscler. Rep. 2015;17:467. doi: 10.1007/s11883-014-0467-4.", "ArticleIdList": ["10.1007/s11883-014-0467-4", "25398643"]}, {"Citation": "Virbagen Omega  Summary of Product Characteristics.  [(accessed on 14 October 2020)]; Available online:  https://www.ema.europa.eu/en/documents/product-information/virbagen-omega-epar-product-information_en.pdf."}, {"Citation": "De Mari K., Maynard L., Eun H.M., Lebreux B. Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled field trial. Vet. Rec. 2003;152:103\u2013108. doi: 10.1136/vr.152.4.105.", "ArticleIdList": ["10.1136/vr.152.4.105", "12572939"]}, {"Citation": "De Mari K., Maynard L., Sanguer A., Lebreux B., Eun H.M. Therapeutic effects of recombinant feline interferon-omega on feline leukemia virus (FeLV)-infected and FeLV/feline immunodeficiency virus (FIV)-coinfected symptomatic cats. J. Vet. Intern. Med. 2004;18:477\u2013482. doi: 10.1892/0891-6640(2004)18<477:TEORFI>2.0.CO;2.", "ArticleIdList": ["10.1892/0891-6640(2004)18<477:TEORFI>2.0.CO;2", "15320583"]}, {"Citation": "Litzlbauer P., Weber K., Mueller R.S. Oral and subcutaneous therapy of canine atopic dermatitis with recombinant feline interferon omega. Cytokine. 2014;66:54\u201359. doi: 10.1016/j.cyto.2013.12.001.", "ArticleIdList": ["10.1016/j.cyto.2013.12.001", "24548425"]}, {"Citation": "TruScient  Summary of Product Characteristics.  [(accessed on 14 October 2020)]; Available online:  https://www.ema.europa.eu/en/documents/product-information/truscient-epar-product-information_en.pdf."}, {"Citation": "Govender S., Csimma C., Genant H.K., Valentin-Opran A. Recombinant Human Bone Morphogenetic Protein-2 for Treatment of Open Tibial Fractures. J. Bone Joint Surg. Am. 2002;84:2123\u20132134. doi: 10.2106/00004623-200212000-00001.", "ArticleIdList": ["10.2106/00004623-200212000-00001", "12473698"]}, {"Citation": "ProZinc  Summary of Product Characteristics.  [(accessed on 14 October 2020)]; Available online:  https://www.ema.europa.eu/en/documents/product-information/prozinc-epar-product-information_en.pdf."}, {"Citation": "Restine L.M., Norsworthy G.D., Kass P.H. Loose-control of diabetes mellitus with protamine zinc insulin in cats: 185 cases (2005\u20132015) Can. Vet. J. 2019;60:399\u2013404.", "ArticleIdList": ["PMC6417615", "30992596"]}, {"Citation": "Oncept IL-2  Summary of Product Characteristics.  [(accessed on 14 October 2020)]; Available online:  https://www.ema.europa.eu/en/documents/product-information/oncept-il-2-epar-product-information_en.pdf."}, {"Citation": "Jourdier T.M., Moste C., Bonnet M.C., Delisle F., Tafani J.P., Devauchelle P., Tartaglia J., Moingeon P. Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2) Gene Ther. 2003;10:2126\u20132132. doi: 10.1038/sj.gt.3302124.", "ArticleIdList": ["10.1038/sj.gt.3302124", "14625567"]}, {"Citation": "Imrestor  Summary of Product Characteristics.  [(accessed on 14 October 2020)]; Available online:  https://www.ema.europa.eu/en/documents/product-information/imrestor-epar-product-information_en.pdf."}, {"Citation": "Canning P., Hassfurther R., TerHune T., Rogers K., Abbott S., Kolb D. Efficacy and clinical safety of pegbovigrastim for preventing naturally occurring clinical mastitis in periparturient primiparous and multiparous cows on US commercial dairies. J. Dairy Sci. 2017;100:6504\u20136515. doi: 10.3168/jds.2017-12583.", "ArticleIdList": ["10.3168/jds.2017-12583", "28601453"]}, {"Citation": "Cytopoint  Summary of Product Characteristics.  [(accessed on 14 October 2020)]; Available online:  https://www.ema.europa.eu/en/documents/product-information/cytopoint-epar-product-information_en.pdf."}, {"Citation": "Moyaert H., van Brussel L., Borowski S., Escalada M., Mahabir S.P., Walters R.R., Stegemann M.R. A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client-owned dogs with atopic dermatitis. Vet. Dermatol. 2017;28:593-e145. doi: 10.1111/vde.12478.", "ArticleIdList": ["10.1111/vde.12478", "28906040"]}, {"Citation": "Arti-Cell Forte  Summary of Product Characteristics.  [(accessed on 14 October 2020)]; Available online:  https://www.ema.europa.eu/en/documents/product-information/arti-cell-forte-epar-product-information_en.pdf."}, {"Citation": "Broeckx S.Y., Martens A.M., Bertone A.L., van Brantegem L., Duchateau L., van Hecke L., Dumoulin M., Oosterlinck M., Chiers K., Hussein H., et al. The use of equine chondrogenic-induced mesenchymal stem cells as a treatment for osteoarthritis: A randomised, double-blinded, placebo-controlled proof-of-concept study. Equine Vet. J. 2019;51:787\u2013794. doi: 10.1111/evj.13089.", "ArticleIdList": ["10.1111/evj.13089", "PMC6850029", "30815897"]}, {"Citation": "HorStem  Summary of Product Characteristics.  [(accessed on 14 October 2020)]; Available online:  https://www.ema.europa.eu/en/documents/product-information/horstem-epar-product-information_en.pdf."}, {"Citation": "Van Loon V.J.F., Scheffer C.J.W., Genn H.J., Hoogendoorn A.C., Greve J.W. Clinical follow-up of horses treated with allogeneic equine mesenchymal stem cells derived from umbilical cord blood for different tendon and ligament disorders. Vet. Q. 2014;34:92\u201397. doi: 10.1080/01652176.2014.949390.", "ArticleIdList": ["10.1080/01652176.2014.949390", "25072527"]}, {"Citation": "Eqstim  Information Leaflet.  [(accessed on 14 October 2020)]; Available online:  https://animalsafety.neogen.com/pdf/prodinfo/eqstim.pdf."}, {"Citation": "Flaminio M.J.B.F., Rush B.R., Shuman W. Immunologic function in horses after non-specific immunostimulant administration. Vet. Immunol. Immunopathol. 1998;63:303\u2013315. doi: 10.1016/S0165-2427(98)00111-1.", "ArticleIdList": ["10.1016/S0165-2427(98)00111-1", "9656421"]}, {"Citation": "Vetimmune  Information Leaflet.  [(accessed on 14 October 2020)]; Available online:  https://vetimmune.com/pi-product-information/"}, {"Citation": "Legendre A.M., Kuritz T., Heidel R.E., Baylor V.M. Polyprenyl immunostimulant in feline rhinotracheitis: Randomized placebo-controlled experimental and field safety studies. Front. Vet. Sci. 2017;4 doi: 10.3389/fvets.2017.00024.", "ArticleIdList": ["10.3389/fvets.2017.00024", "PMC5326765", "28289684"]}, {"Citation": "Oncept  Information Leaflet.  [(accessed on 14 October 2020)]; Available online:  https://vcahospitals.com/san-francisco/-/media/vca/documents/services/oncology/oncept_tech_detailer_merial_101012.pdf?la=en&hash=CAEF2F9E230862A1BEFB5A1F77F9E2D3."}, {"Citation": "Grosenbaugh D.A., Leard A.T., Bergman P.J., Klein M.K., Meleo K., Susaneck S., Hess P.R., Jankowski M.K., Jones P.D., Leibman N.F., et al. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am. J. Vet. Res. 2011;72:1631\u20131638. doi: 10.2460/ajvr.72.12.1631.", "ArticleIdList": ["10.2460/ajvr.72.12.1631", "22126691"]}, {"Citation": "Zelnate  Information Leaflet.  [(accessed on 14 October 2020)]; Available online:  https://www.zelnate.com/static/documents/Zelnate-ChallengeStudy_Detailer.pdf."}, {"Citation": "Martin B. Effect of Zelnate Administered as a Metaphylactic upon Initial Processing of High-Risk, Newly Received Beef Calves on Performance and Morbidity. Animal Science Undergraduate Honors Theses.  [(accessed on 20 May 2020)];2020  Available online:  https://scholarworks.uark.edu/anscuht/41."}, {"Citation": "Victrio  Information Leaflet.  [(accessed on 14 October 2020)]; Available online:  https://www.bayerlivestock.com/static/documents/Livestock/pdf%20documents/VCT151070_Victrio_Master_Detailer.pdf."}, {"Citation": "Ilg T. The immunostimulator Victrio activates chicken toll-like receptor 21. Vet. Immunol. Immunopathol. 2020;220:109977. doi: 10.1016/j.vetimm.2019.109977.", "ArticleIdList": ["10.1016/j.vetimm.2019.109977", "31760146"]}, {"Citation": "Staphage lysaten Information Leaflet.  [(accessed on 14 October 2020)]; Available online:  https://delmontlabs.com/wp-content/uploads/2016/11/Package-Insert.pdf."}, {"Citation": "Solomon S.E.B., de Farias M.R., Pimpao C.T. Use of Staphylococcus aureus Phage Lysate Staphage Lysate (SPL)\u00ae for the Control of Recurrent Pyoderma Eczema in Dogs with Atopic Dermatitis. Acta Sci. Vet. 2016;44:1382. doi: 10.22456/1679-9216.81103.", "ArticleIdList": ["10.22456/1679-9216.81103"]}, {"Citation": "Immunocidin Equine  Information Leaflet.  [(accessed on 14 October 2020)]; Available online:  http://novavive.ca/uploads/products/files/3923-us-immunocidinequine-brochure-06-17-hrz.pdf."}, {"Citation": "Caston S.S., Sponseller B.A., Dembek K.A., Hostetter J.M. Evaluation of Locally Injected Mycobacterium Cell Wall Fraction in Horses with Sarcoids. J. Equine Vet. Sci. 2020;90:103102. doi: 10.1016/j.jevs.2020.103102.", "ArticleIdList": ["10.1016/j.jevs.2020.103102", "32534762"]}, {"Citation": "Pluset  Characteristics of the Veterinary Medicinal Product (ChPLW)  [(accessed on 14 October 2020)]; Available online:  http://plw.urpl.gov.pl/files/PLUSET_charakterystyka.pdf."}, {"Citation": "PG600  Summary of Product Characteristics.  [(accessed on 14 October 2020)]; Available online:  https://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_10996-025-001_17102016100943.pdf."}, {"Citation": "Folligon  Summary of Product Characteristics.  [(accessed on 14 October 2020)]; Available online:  https://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_10996-055-001_21032017164937.pdf."}, {"Citation": "Folltropin  Information Leaflet.  [(accessed on 14 October 2020)]; Available online:  http://plw.urpl.gov.pl/files/Folltropin_ulotka_inf.pdf."}, {"Citation": "Jangra P., Singh A. Staphylococcus aureus \u03b2-hemolysin-neutralizing single domain antibody isolated from phage display library of Indian desert camel. Asian Pac. J. Trop. Med. 2010;3:1\u20137. doi: 10.1016/S1995-7645(10)60020-X.", "ArticleIdList": ["10.1016/S1995-7645(10)60020-X"]}, {"Citation": "Zhang T., Wang C.Y., Zhang W., Gao Y.W., Yang S.T., Wang T.C., Zhang R., Qin C., Xia X.Z. Generation and characterization of a fusion protein of single chain fragment variable antibody against hemagglutinin antigen of avian influenza virus and truncated protamine. Vaccine. 2010;28:3949\u20133955. doi: 10.1016/j.vaccine.2010.03.045.", "ArticleIdList": ["10.1016/j.vaccine.2010.03.045", "20382243"]}, {"Citation": "Corti D., Voss J., Gamblin S.J., Codoni G., Macagno A., Jarrossay D., Vachieri S.G., Pinna D., Minola A., Vanzetta F., et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011;333:850\u2013856. doi: 10.1126/science.1205669.", "ArticleIdList": ["10.1126/science.1205669", "21798894"]}, {"Citation": "Wang M., Zhang Y., Li B., Zhu J. Construction of scFv that bind both fibronectin-binding protein A and clumping factor A of Stapylococcus aureus. Res. Vet. Sci. 2015;100:109\u2013114. doi: 10.1016/j.rvsc.2015.02.012.", "ArticleIdList": ["10.1016/j.rvsc.2015.02.012", "25910693"]}, {"Citation": "Zhang Y., Yin J., Li T., Zhou B., Xu P., Che R., Liu Y., Cao H., Ye X., Yang Y., et al. A recombinant avian antibody against VP2 of infectious bursal disease virus protects chicken from viral infection. Res. Vet. Sci. 2017;114:194\u2013201. doi: 10.1016/j.rvsc.2017.04.003.", "ArticleIdList": ["10.1016/j.rvsc.2017.04.003", "28482266"]}, {"Citation": "Enomoto M., Mantyh P.W., Murrell J., Innes J.F., Lascelles B.D.X. Anti-nerve growth factor monoclonal antibodies for the control of pain in dogs and cats. Vet. Rec. 2019;184:23. doi: 10.1136/vr.104590.", "ArticleIdList": ["10.1136/vr.104590", "PMC6326241", "30368458"]}]}], "History": [{"Year": "2020", "Month": "11", "Day": "26"}, {"Year": "2020", "Month": "12", "Day": "3"}, {"Year": "2020", "Month": "12", "Day": "7"}, {"Year": "2020", "Month": "12", "Day": "15", "Hour": "1", "Minute": "4"}, {"Year": "2020", "Month": "12", "Day": "16", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "12", "Day": "16", "Hour": "6", "Minute": "1"}, {"Year": "2020", "Month": "12", "Day": "9"}], "PublicationStatus": "epublish", "ArticleIdList": ["33316993", "PMC7763151", "10.3390/ani10122343", "ani10122343"]}}]}